🔗 Share this article America and Britain Strike Zero-Tariff Pact on Prescription Drugs. Stock image of medicine trade. Britain and America have signed a important trade agreement that will keep no import taxes on UK pharmaceutical products being sold in the US market. The Terms of the Pact Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital products will be held at zero for a timeframe of the next three years. This development comes after recent threats to dramatically increase import taxes on patented pharmaceutical imports, with figures floated reaching one hundred percent. "This agreement between the Britain bolsters the international landscape for cutting-edge drugs and establishes much-needed equity to transatlantic drug exports," an announcement noted. Commercial Impact Drugs constitute one of the Britain's biggest export categories to the America, which is by far the largest buyer for major companies like GSK and AstraZeneca. Export figures indicate that in the one-year period to the end of last September, the UK shipped drugs worth over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that period. "This deal protects jobs, boosts investment and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented. Detailed NHS Changes The agreement entails several key changes from the UK: Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by a quarter. Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years. Payback Limit: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, repayments topped 20%. Industry Background This agreement follows a long-running tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption. This friction were intensified by assertions that American patients were charged several times more for the equivalent treatments than people in the Britain and the EU. Recently, several major drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward projects in the United States. A senior figure publicly accepted that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the past decade.
Stock image of medicine trade. Britain and America have signed a important trade agreement that will keep no import taxes on UK pharmaceutical products being sold in the US market. The Terms of the Pact Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital products will be held at zero for a timeframe of the next three years. This development comes after recent threats to dramatically increase import taxes on patented pharmaceutical imports, with figures floated reaching one hundred percent. "This agreement between the Britain bolsters the international landscape for cutting-edge drugs and establishes much-needed equity to transatlantic drug exports," an announcement noted. Commercial Impact Drugs constitute one of the Britain's biggest export categories to the America, which is by far the largest buyer for major companies like GSK and AstraZeneca. Export figures indicate that in the one-year period to the end of last September, the UK shipped drugs worth over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that period. "This deal protects jobs, boosts investment and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented. Detailed NHS Changes The agreement entails several key changes from the UK: Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by a quarter. Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years. Payback Limit: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, repayments topped 20%. Industry Background This agreement follows a long-running tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption. This friction were intensified by assertions that American patients were charged several times more for the equivalent treatments than people in the Britain and the EU. Recently, several major drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward projects in the United States. A senior figure publicly accepted that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the past decade.